Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN SP versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN SP versus POKONZA.
CORDRAN SP vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid